Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 39: EUROPA-Studie - Endpunkte Abb. 40: EUROPA-Studie - Subgruppenanalyse Abb. 41: EUROPA-Studie - Subgruppenanalyse Aktuelles Bild - Abb. 42: EUROPA-Studie - Subgruppenanalyse Abb. 43: EUROPA-Studie - Sekundäre Endpunkte Abb. 44: EUROPA-Studie - Myokardinfarkt Abb. 45: EUROPA-Studie - Hospitalisierung Zum letzten Bild
Abbildung 42: EUROPA-Studie - Subgruppenanalyse
Consistency of benefits with perindopril is shown in all patients whether they were using lipid lowering drugs, b-blockers and Calcium-channel blockers, or not. Almost all patients were using platelet inhibitors and more than half of them, lipid lowering drugs. By further analysis, no drug interaction was found meaning that benefits with perindopril are independent of other drugs.
 
EUROPA-Studie - Subgruppenanalyse
Vorheriges Bild Nächstes Bild   


Abbildung 42: EUROPA-Studie - Subgruppenanalyse
Consistency of benefits with perindopril is shown in all patients whether they were using lipid lowering drugs, b-blockers and Calcium-channel blockers, or not. Almost all patients were using platelet inhibitors and more than half of them, lipid lowering drugs. By further analysis, no drug interaction was found meaning that benefits with perindopril are independent of other drugs.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung